NEW YORK (GenomeWeb News) – Waters said today that the Chinese Food and Drug Administration has approved registration of its Acquity UPLC TQD system for sale as a medical device for routine diagnostic applications and neonatal metabolites disease screening.

The device is the second of Waters to receive Chinese approval for in vitro diagnostic applications. In 2008, the CFDA approved a neonatal screening test on the company's Quattro micro mass spec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.